CURRENT STATUS OF ENDOCRINE TREATMENT OF CARCINOMA OF THE BREAST

被引：12

作者：

BUZDAR, AU

机构：

[1] Department of Medical Oncology (Medical Breast Service), University of Texas M.D. Anderson Cancer Center, Houston

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 02期

关键词：

combined therapy; hormonochemo‐adjuvant therapy; sequential therapy; tamoxifen; therapy;

D O I：

10.1002/ssu.2980060205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sequential administration of endocrine therapies can result in objective remission in a significant fraction of patients with metastatic breast cancer. Combined hormonal therapies and combined hormonochemothera‐pies have not resulted in better results than the sequential administration of these same therapies. Tamoxifen (an antiestrogen) given as an initial therapy results in local control of the disease in a significant fraction of patients with locally advanced breast cancer who are not candidates for cytotoxic therapy. Tamoxifen as an adjuvant therapy for operable breast cancer prolongs disease‐free survival and reduces mortality in patients >50 yr of age with higher estrogen receptor concentrations The role of tamoxifen as adjuvant therapy for patients <50 yr of age remains unclear. Also, adjuvant tamoxifen in combination with cytotoxic drugs has not produced superior results, and the duration of adjuvant tamoxifen therapy remains to be determined. Experimental data suggest prolonged administration of tamoxifen may be needed to control microme‐tastases. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：77 / 82

页数：6

共 61 条

[1]

Beatson GT, On the treatment of inoperable cases of carcinoma of the mamma: Suggestion for a new method of treatment, with illustrative cases, Lancet, 2, pp. 104-107, (1896)

[2]

Huggins C, Bergenstal DM, Inhibition of human mammary and prostatic cancer by adrenalectomy, Cancer Res, 12, pp. 134-141, (1952)

[3]

Luft R, Olivercrona H, Ikkos D, Et al., Hypophysectomy in the management of metastatic cancer in the breast, Endocrine Aspects of Breast Cancer, pp. 27-35, (1958)

[4]

Williams MR, Walker KJ, Turkes A, Et al., The use of an LH‐RH agonist (Zoladex) in advanced premenopausal breast cancer, Br J Cancer, 53, pp. 629-636, (1986)

[5]

Harvey HA, Lipton A, Santen RJ, Et al., Phase II study of a gonadotropin releasing hormone analogue Leuprolide, in post‐menopausal advanced cancer patients (C‐436), Proc Am Soc Clin Oncol, 22, (1981)

[6]

Jensen EV, Jacobson HI, Basic guides to the mechanism of estrogen action, Recent Prog Horm Res, 18, pp. 387-414, (1962)

[7]

McGuire WL, De La Garza M, Chamness GC, Evaluation of estrogen receptor assays in human breast cancer tissue, Cancer Res, 37, pp. 637-639, (1977)

[8]

Milgrom E, Atger M, Perrot M, Et al., Progesterone in uterus and plasma: Uterine progesterone receptors during the estrous cycle and implantation in the guinea pig, Endocrinology, 90, (1972)

[9]

Horwitz KB, McGuire WL, Specific progesterone receptors in human breast cancer, Steroids, 25, (1975)

[10]

Sherman M, Pickering L, Rollwagen FM, Et al., Mero‐receptors: Proteolytic fragments of receptors containing the steroid binding site, Fed Proc, 37, pp. 167-175, (1978)

← 1 2 3 4 5 6 7 →